Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SERA PROGNOSTICS, INC.
Report date July 12, 2023 · Filed July 12, 2023
Section 16 reporting ended · disclosed 2023-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 8, 2023 00:49 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 42,700 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001534969-23-000013 · wf-form4_167823655156888.xml · derivative · entry 2 Foley Michael R · CIK 0001892321 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,700 Underlying: Class A Common Stock · 42,700 shares Expires 2033-03-06 F2 · derivative.exercise_date: These stock options vest over four years as follows: 1/48 of the original grant amount vests in monthly installments for four years following the vesting commencement date, which is March 6, 2023, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 00:49 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001534969-23-000013 · wf-form4_167823655156888.xml · nonDerivative · entry 1 Foley Michael R · CIK 0001892321 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 1/4 of the original grant amount vests in annual installments for four years following the vesting commencement date, which is March 6, 2023, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 23:06 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 276,000 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001534969-22-000004 · wf-form4_164367039214000.xml · derivative · entry 1 Foley Michael R · CIK 0001892321 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,000 Underlying: Class A Common Stock · 276,000 shares Expires 2032-01-28 F1 · derivative.exercise_date: These stock options vest over four years as follows: 25% of the original grant amount vests on the first anniversary of the vesting commencement date, which is January 28, 2022, and 1/36 of the remaining amount vests in monthly installments for three years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.